Bin Hu

Bin Hu

Auto-generated profile, based on publicly available information

Bin Hu

Department of Pharmacy the First Affiliated Hospital of Army Medical University (Third Military Medical University) Chongqing China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
XLXingxing Li
Xingxing Li
LZLin Zhang
Lin Zhang
SHSang Hu
Sang Hu
DLDan Liu
Dan Liu
BHBin Hu
Bin Hu
JHJing Hu
Jing Hu

7 April 2023 in Frontiers in Physiology
Verified
Journal Article
Open access
DLDan Liu
Dan Liu
XLXingxing Li
Xingxing Li
LZLin Zhang
Lin Zhang
BHBin Hu
Bin Hu
SHSang Hu
Sang Hu
JHJing Hu
Jing Hu
Osteoarthritis (OA) is one of the common degenerative joint diseases in clinic. It mainly damages articular cartilage, causing pain, swelling and stiffness around joints, and is the main cause of disability of the elderly. Due to the unclear pathogenesis of osteoarthritis and the poor self-healing ability of articular cartilage, the treatment options for this disease are limited. At present, NSAIDs, Glucocorticoid and Duloxetine are the most commonly used treatment choice for osteoarthritis. Although it is somewhat effective, the adverse reactions are frequent and serious. The development of safer and more effective anti-osteoarthritis drugs is essential and urgent. This review summarizes recent advances in the pharmacological treatment of OA, focusing on small molecule inhibitors targeting cartilage remodeling in osteoarthritis as well as the research idea of reducing adverse effects by optimizing the dosage form of traditional drugs for the treatment of osteoarthritis. It should provide a reference for exploration of new potential treatment options.

1 January 2021 in Indian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
BHBin Hu
Bin Hu
WCWanjiao Chen
Wanjiao Chen
SSshi-fang sun
shi-fang sun
YMYifeng Mai
Yifeng Mai
DZDecai Zhu
Decai Zhu
To investigate the diagnostic value of chitinase-3-like protein 1 and keratin 5 in bronchoalveolar lavage fluid in 88 patients with lung disease. This was a case control study to collect 50 patients with lung cancer (malignant disease group) and 38 patients with benign lung disease (benign disease group) who were admitted to the respiratory medicine department in the affiliated hospital of medical school of Ningbo university from December 2019 to March 2020. The enzyme-linked immunosorbent assay was applied to detect the expression levels of chitinase-3-like protein 1 and keratin 5 in bronchoalveolar lavage fluid of the two groups of the patients. The diagnostic effect was evaluated using the subject's working characteristics to establish a diagnostic mathematical model. The levels of chitinase-3-like protein 1 and keratin 5 in bronchoalveolar lavage fluid were significantly higher in the malignant disease group than in the benign disease group (p<0.05). These two (chitinase-3-like protein 1 and keratin 5) were significantly correlated and positively correlated and the combined test could significantly improve the sensitivity and specificity of lung cancer diagnosis. The diagnostic rate of chitinase-3-like protein 1 and keratin 5 for lung cancer. The chitinase-3-like protein 1 in bronchoalveolar lavage fluid and carcinoembryonic antigen in blood combined was superior to chitinase-3- like protein 1 or keratin 5 alone in the diagnosis of lung cancer. Chitinase-3-like protein 1 and keratin 5 in bronchoalveolar lavage fluid contribute to the early diagnosis of lung cancer and can be used as biomarkers for the diagnosis of lung cancer with high sensitivity and specificity. The application of the two combined assays as molecular markers for clinical diagnosis and as targeted therapeutic agents needs to be further studied.